Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo
repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.
Marzano AV, Narcisi A, Tavoletti G, Rossi LC, Romagnuolo M, Bianco M, Amerio P, Morea E, Provenzano E, Rongioletti F, Guida S, Pinto LM, D'Amore A, Fargnoli MC, Pacifico A, Iacovelli P, Rubegni P, Trovato E, Romanelli M, Michelucci A, Micali G, Musumeci ML, Di Marco AL, Napolitano M, Coronella L, Foti C, Borghi A, Pacetti L, Giacalone S, Spigariolo CB, Nazzaro G, Ribero S, Mastorino L, Belloni Fortina A, Sernicola A, Simonetti O, Matteucci M, Nettis E, Stingeni L, Pellacani G, Dattola A, Zalaudek I, Caposiena Caro RD, Antiga E, Baffa ME, Esposito M, Bruni M, Sena P, Vezzoli P, Rocca L, Cozzani E, Gasparini G, Capurro N, Savoia P, Calzavara-Pinton P, Arisi M, Carlo T, Michelerio A, Barruscotti S, Picardo M, Paganelli A, Malagoli P, Pileri A, Giuffrida R, Mercuri SR, Bianchi VG, Argenziano G, Fulgione E, Girolomoni G, Maurelli M, Costanzo A, Cartocci A, Peris K, Alberti-Violetti S
British Journal of DermatologyIn the feed 17 Aug 2026, published online 17 Aug 2026, issue 2026 Aug 17, added to PubMed 17 Aug 2026
Topics: Pigmentary disorders
Abstract
BACKGROUNDVitiligo affects 0·5-2% of the global population and carries a substantial psychosocial burden. Topical ruxolitinib 1·5% cream is approved for non-segmental vitiligo based on phase-3 trial data, but real-world evidence across heterogeneous populations remains limited.
OBJECTIVESTo evaluate the real-world effectiveness, safety, and patient-reported outcomes of topical ruxolitinib across 34 Italian dermatology centres, and to identify possible clinical predictors of treatment response.
METHODSMulticentre retrospective cohort study (July 2024-October 2025). Patients (≥12 years) with non-segmental vitiligo received ruxolitinib 1·5% cream twice daily. Primary outcomes were F-VASI75 and F-VASI90 at 24 and 52 weeks. Secondary outcomes were VNS, DLQI, VitiQoL, GAD-7, and PHQ-9.
RESULTS860 patients (mean age 47 years; 58% female; disease duration 13·5 years; 84% previously treated) completed 24-week assessment; 229 (26·6%) had reached 52 weeks at the time of data lock. F-VASI75 was achieved by 18·5% at 24 weeks, increasing to 38·4% at 52 weeks; F-VASI90 rose from 5·7% to 25·8%. In multivariable logistic regression, summer treatment initiation (adjusted OR 6·7, 95% CI 2·7-16·8) and Koebner phenomenon (adjusted OR 1·6, 95% CI 1·04-2·66) were independent predictors of F-VASI75 at 24 weeks. At baseline, 37% of patients had moderate-to-severe anxiety (GAD-7 ≥10); this fell to 11% at 24 weeks and 2% at 52 weeks. VitiQoL, DLQI, and PHQ-9 improved at all timepoints. Adverse events were mild in 98·9%; treatment discontinuation rate was 1·5%.
CONCLUSIONSIn a large real-world population considerably more heterogeneous than registration trial cohorts, topical ruxolitinib showed progressive repigmentation through 52 weeks with excellent tolerability. Summer initiation and Koebner phenomenon independently predicted early response, findings that may inform patient counselling and the design of prospective studies. The parallel sustained reduction in anxiety and depression argues for standardised mental health assessment as a routine component of vitiligo care.
Abstract from PubMed
PMID 42605165 · DOI 10.1093/bjd/ljag342